Skip to content

This Site is Intended for Healthcare Professionals Only

Search AI Powered

Latest Stories

Industry body welcomes FSA update on CBD products

The Association for the Cannabinoid Industry has said that the Food Standards Agency has updated the criteria for CBD products which can remain on sale from 1 April 2021.

Previously, only products which were on sale at the time of the FSA’s announcement (13 February 2020) and were linked to an application which had been validated by 31 March 2021 were to be included.


To maximise the opportunity to pass validation, this now includes all products on sale on 13 February 2020 and linked to an application submitted before 31 March 2021 that is subsequently validated.

All applications must be submitted by March 31, however.

This is an update to the previous stance that all products must be validated by that date. The FSA reiterates that these products must have been on the market prior to February 13 and be linked to a validated dossier.

The FSA will also publish a list of products linked to validated applications in April, with regular updates to this list as and when dossiers are validated.

Products that have not met the full requirements, but have satisfied the FSA that they will do so, will be listed providing that they include “robust plans” to complete the risk assessment process in their submission.

Meanwhile, the ACI is seeking clarity from the FSA that these companies will continue to be allowed to sell their products.

A list of products linked to validated applications will be published on the FSA’s website in April and regularly updated.

The FSA will also publish a list of products associated with applications which have not yet fully met the legal requirements to be validated but have set out sufficiently robust plans to prove they are fully committed to delivering the remaining information required.

This will include evidence of plans to complete the risk assessment process, with a clear deadline for submission of the outstanding information.

The new update from the FSA means the deadline is now for submission by March 31 and not validation. “If you have not yet submitted your dossier, due to time constraints in regards to having your dossier validated before March 31 2021, you should look to submit your dossier as soon as possible,” ACI said.

In its latest update, the FSA said CBD businesses should continue to submit their novel food applications before the 31 March 2021 deadline.

Emily Miles, chief executive of the Food Standards Agency, said: "Applying for novel food authorisation is the only way CBD products can remain on sale here. For the past year, we’ve been encouraging all businesses to submit good quality applications as a matter of urgency.

"However, we have received a large number of applications close to the deadline. This means that, in order to process these properly, we are adapting the criteria of products allowed to remain on sale from 1 April.

"For some time now we’ve been supporting a pragmatic and proportionate approach to CBD regulation. Our commitment to ensuring that consumers know these products are being checked for safety remains firm."

More For You

Pharmacy sector leaders meet with MPs to discuss 'value pharmacies bring to local communities'

Sadik Al-Hassan revealed how his career as a pharmacist has helped shape him as a politician

Pharmacy sector leaders meet with MPs to discuss 'value pharmacies bring to local communities'

Sadik Al-Hassan revealed how his career as a pharmacist has helped shape him as a politician at an event in Parliament last week where LPC chairs and Community Pharmacy England (CPE) met with MPs.

The Labour MP for North Somerset, who spent over two decades working as a community pharmacist, spoke about his experiences as a former member of Avon LPC and how many of the skills he learned during that time, such as influencing, have helped in his role as an MP.

Keep ReadingShow less
Bacteria E.coli to convert plastic waste into a popular painkiller

Paracetamol is one of the most commonly used drugs worldwide

Pic credit: iStock

E.coli can turn plastic into painkillers, chemists discover

Key Summary

  • Chemists used a molecule derived from PET plastic to spark a chemical reaction in a strain of E.coli
  • The chemists were able to transform their molecule into acetaminophen, also known as paracetamol
  • Sceptics said this isn't significant enough to tackle the massive plastic pollution problem

Scientists have found a way to use the bacteria E.coli to convert plastic waste into a popular painkiller, a study said on Monday (23), though outside experts doubted the technique would make a dent in the fight against plastic pollution.

Keep ReadingShow less
Alphega Pharmacy Conference

Attendees at the Alphega Conference

Alphega Pharmacy Conference highlights importance of embracing technology

Key Summary

  • Alphega members discussed clinical, operational and digital changes in primary care
  • Practical insights to streamline operations and strengthen pharmacists role as frontline healthcare providers

Alphega Pharmacy held its annual conference on Sunday (22) with a focus on how technology and AI can transform healthcare.

Keep ReadingShow less
Home cervical screening kits in England

Government data states that around five million women are still not attending cervical screenings

Getty Images

Home cervical screening kits launched in England

Key Summary

  • NHS England has launched at-home cervical screening kits to improve uptake among women aged 25 to 64.
  • The discreet kits aim to overcome barriers like embarrassment and increase screening rates from 68.8 per cent towards the 80 per cent target.
  • Early diagnosis through home testing is expected to boost survival rates and help tackle cervical cancer for all communities.

NHS England has created an innovative at-home human papillomavirus (HPV) testing, for women who are yet to take cervical screening service.

Keep ReadingShow less
NHS warns doctors using unapproved  AI Software

NHS England has demanded that GPs and hospitals stop using artificial intelligence software that could breach data protection rules.

iStock

NHS warns doctors against use of unapproved AI software

Key Summary

  • NHS wants GPs and hospitals to stop using dubious artificial intelligence software during patient meetings
  • It had in April urged the doctors to use AI for notetaking using Ambient Voice Technology software
  • But it now claims that many AVT suppliers, who fail to meet NHS governance standards, are selling them to doctors
  • British Medical Association officials want the NHS to help doctors choose the safe AVT software

Doctors have been warned against the use of AI software that does not meet minimum standards to record and transcribe patient meetings.

Keep ReadingShow less